Author Archives: Katie Gottschalk



By | Leave a Comment

In an international game of Whac-A-Mol, this week China announced that it would be adding four lethal heroin-like narcotics to a list of controlled substances to help combat the growing opioid epidemic in America. The primary target of the ban is Carfentanil, one of the latest and deadliest synthetic opioids to show up in the […]

Posted in FDA, Global Health, Health reform, Trade, uncategorized ;


When the Status Quo Feels like a Victory

By | Leave a Comment

This week Polish residents took to the streets. Dressed in black, they stood together in protest of a complete ban on access to abortion in their already conservative country. In Poland’s Communist era of the 1960s and 70s, abortions were easily available and cheap, with other European women even making the trip across the Iron […]

Posted in Health reform, Human Rights, uncategorized ;


The Exorbitant Pricing of Pharmaceuticals is in the News. Again.

By | Leave a Comment

This week the pharmaceutical pricing discussion centers on Mylan, and its 548% boost in the price of EpiPens. The press coverage and industry promises are a familiar scene: a large drug company buys a well-established medication or technology, and then raises the price. There is outrage, there are statements of promises and remedies, and then […]

Posted in FDA, Global Health, uncategorized ;

Stay Informed

Signup for our mailing list and stay up to date on the latest happenings at The O’Neill Institute

Or sign up for our RSS Feed

The views reflected in this blog are those of the individual authors and do not necessarily represent those of the O’Neill Institute for National and Global Health Law or Georgetown University. This blog is solely informational in nature, and not intended as a substitute for competent legal advice from a licensed and retained attorney in your state or country.

See the full disclaimer and terms of use.